• SyncroPatch 384/768i

    APC with highest throughput on the market
  • SyncroPatch 384/768i

    384 cells in parallel => upgradable to 768
  • SyncroPatch 384/768i

    True HTS AND Gigaohm seals
  • SyncroPatch 384/768i

    Analysis Software even more powerful than before
  • SyncroPatch 384/768i

    Assay flexibility via high tech

2019 - Spectrum of KV2.1 Dysfunction in KCNB1‐Associated Neurodevelopmental Disorders

icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 384/768i) Publication Annals of Neurology (2019)

Kang, S.K., Vanoye, C.G., Misra, S.N., Echevarria, D.M., Calhoun, J.D., O’Connor, J.B., Fabre, K.L., McKnight, D., Demmer, L., Goldenberg, P., Grote, L.E., Thiffault, I., Saunders, C., Strauss, K.A., Torkamani, A., van der Smagt, J., van Gassen, K., Carson, R.P., Diaz, J., Leon, E., Jacher, J.E., Hannibal, M.C., Litwin, J., Friedman, N.R., Schreiber, A., Lynch, B., Poduri, A., Marsh, E.D., Goldberg, E.M., Millichap, J.J., George Jr., A.L., Kearney, J.A.

Annals of Neurology (2019) doi.org/10.1002/ana.25607



Pathogenic variants in KCNB1, encoding the voltage‐gated potassium channel KV2.1, are associated with developmental and epileptic encephalopathy (DEE). Previous functional studies on a limited number of KCNB1 variants indicated a range of molecular mechanisms by which variants affect channel function, including loss of voltage sensitivity, loss of ion selectivity, and reduced cell‐surface expression.


We evaluated a series of 17 KCNB1 variants associated with DEE or other neurodevelopmental disorders (NDDs) to rapidly ascertain channel dysfunction using high‐throughput functional assays. Specifically, we investigated the biophysical properties and cell‐surface expression of variant KV2.1 channels expressed in heterologous cells using high‐throughput automated electrophysiology and immunocytochemistry–flow cytometry.


Pathogenic variants exhibited diverse functional defects, including altered current density and shifts in the voltage dependence of activation and/or inactivation, as homotetramers or when coexpressed with wild‐type KV2.1. Quantification of protein expression also identified variants with reduced total KV2.1 expression or deficient cell‐surface expression.


Our study establishes a platform for rapid screening of KV2.1 functional defects caused by KCNB1 variants associated with DEE and other NDDs. This will aid in establishing KCNB1 variant pathogenicity and the mechanism of dysfunction, which will enable targeted strategies for therapeutic intervention based on molecular phenotype.

Download here

Back to Overview

SyncroPatch 384i brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.